Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis-Reference-Cited by-同舟云学术

Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis

Published:2017-03-17 Issue:1 Volume:7 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Komiya Chikara,Tanaka Miyako,Tsuchiya Kyoichiro,Shimazu Noriko,Mori Kentaro,Furuke Shunsaku,Miyachi Yasutaka,Shiba Kumiko,Yamaguchi Shinobu,Ikeda Kenji,Ochi Kozue,Nakabayashi Kazuhiko,Hata Ken-ichiro,Itoh Michiko,Suganami Takayoshi,Ogawa Yoshihiro

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/srep44754.pdf

Reference49 articles.

1. Zeisberg, M. & Kalluri, R. Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis. Am J Physiol Cell Physiol 304, C216–225, doi: 10.1152/ajpcell.00328.2012 (2013).

2. Ratziu, V., Bellentani, S., Cortez-Pinto, H., Day, C. & Marchesini, G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 53, 372–384, doi: 10.1016/j.jhep.2010.04.008 (2010).

3. Chalasani, N. et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55, 2005–2023, doi: 10.1002/hep.25762 (2012).

4. Cohen, J. C., Horton, J. D. & Hobbs, H. H. Human fatty liver disease: old questions and new insights. Science 332, 1519–1523, doi: 10.1126/science.1204265 (2011).

5. Malhi, H. & Gores, G. J. Cellular and molecular mechanisms of liver injury. Gastroenterology 134, 1641–1654, doi: 10.1053/j.gastro.2008.03.002 (2008).

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pirfenidone ameliorates ANIT-induced cholestatic liver injury via modulation of FXR, NF-кB/TNF-α, and Wnt/GSK-3β/β-catenin signaling pathways;Toxicology and Applied Pharmacology;2024-09

2. Pirfenidone use in fibrotic diseases: What do we know so far?;Immunity, Inflammation and Disease;2024-07

3. Aging-associated Cyst Formation and Fibrosis;YAKUGAKU ZASSHI;2024-04-01

4. Current investigations for liver fibrosis treatment: between repurposing the FDA-approved drugs and the other emerging approaches;Journal of Pharmacy & Pharmaceutical Sciences;2023-11-07

5. Busulfan-induced hepatic sinusoidal endothelial cell injury: Modulatory role of pirfenidone for therapeutic purposes;Toxicology in Vitro;2023-10